Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

ROR1: an orphan becomes apparent
Thomas J. Kipps
Blood (2022) Vol. 140, Iss. 14, pp. 1583-1591
Open Access | Times Cited: 53

Showing 1-25 of 53 citing articles:

Chronic Lymphocytic Leukemia: 2025 Update on the Epidemiology, Pathogenesis, Diagnosis, and Therapy
Michael Hallek
American Journal of Hematology (2025)
Open Access | Times Cited: 4
State of the Art in CAR-T Cell Therapy for Solid Tumors: Is There a Sweeter Future?
Beatriz Amorós-Pérez, Benigno Rivas-Pardo, Manuel Gómez del Moral, et al.
Cells (2024) Vol. 13, Iss. 9, pp. 725-725
Open Access | Times Cited: 12
The signaling pathways activated by ROR1 in cancer
María Josefina Quezada, Pablo Lopez‐Bergami
Cellular Signalling (2023) Vol. 104, pp. 110588-110588
Closed Access | Times Cited: 21
WNT5B drives osteosarcoma stemness, chemoresistance and metastasis
Rachel S. Perkins, Glenn Murray, Sarocha Suthon, et al.
Clinical and Translational Medicine (2024) Vol. 14, Iss. 5
Open Access | Times Cited: 8
Armored TGFβRIIDN ROR1-CAR T cells reject solid tumors and resist suppression by constitutively-expressed and treatment-induced TGFβ1
Tri Tran, Bal Krishna Chand Thakuri, Saule Nurmukhambetova, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 4, pp. e008261-e008261
Open Access | Times Cited: 7
Structure and function of the ROR2 cysteine-rich domain in vertebrate noncanonical WNT5A signaling
Samuel C. Griffiths, Jia Tan, Armin Wagner, et al.
eLife (2024) Vol. 13
Open Access | Times Cited: 6
CAR Based Immunotherapy of Solid Tumours—A Clinically Based Review of Target Antigens
John Maher, David M. Davies
Biology (2023) Vol. 12, Iss. 2, pp. 287-287
Open Access | Times Cited: 14
Delineating the role of nuclear receptors in colorectal cancer, a focused review
Mukesh Kumar Manickasamy, Sujitha Jayaprakash, Sosmitha Girisa, et al.
Discover Oncology (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 5
A phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer
Rebecca Shatsky, Hemali Batra-Sharma, Teresa Helsten, et al.
Breast Cancer Research (2024) Vol. 26, Iss. 1
Open Access | Times Cited: 5
Progresses of T-cell-engaging bispecific antibodies in treatment of solid tumors
Junjun Liu, Jianwei Zhu
International Immunopharmacology (2024) Vol. 138, pp. 112609-112609
Closed Access | Times Cited: 5
Current status and future challenges of CAR-T cell therapy for osteosarcoma
Shizhe Li, He Zhang, Guanning Shang
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 12
ROR1 expression in mature B lymphoid neoplasms by flow cytometry
Flávia Arandas de Sousa, Nádila Magalhães Millan, Rodolfo Patussi Correia, et al.
Cytometry Part B Clinical Cytometry (2024) Vol. 106, Iss. 1, pp. 74-81
Closed Access | Times Cited: 4
Hairy cell leukemia 2024: Update on diagnosis, risk‐stratification, and treatment—Annual updates in hematological malignancies
Xavier Troussard, Elsa Maître, Jérôme Paillassa
American Journal of Hematology (2024) Vol. 99, Iss. 4, pp. 679-696
Closed Access | Times Cited: 4
CAR-T Therapy Beyond B-Cell Hematological Malignancies
Martina Canichella, Paolo de Fabritiis
Cells (2025) Vol. 14, Iss. 1, pp. 41-41
Open Access
ROR1 CAR-T cells and ferroptosis inducers orchestrate tumor ferroptosis via PC-PUFA2
Dan Li, Wenjie Zhang, Ruiheng Wang, et al.
Biomarker Research (2025) Vol. 13, Iss. 1
Open Access
Discovery of the First Potent ROR1 Degrader for the Treatment of Non-Small Cell Lung Cancer
Jinlin Li, Lin Li, Hou Cai-yun, et al.
European Journal of Medicinal Chemistry (2025), pp. 117325-117325
Closed Access
Exogenous N-Acetylgalactosamine-4-sulfatase (Arylsulfatase B) Leads to Melanoma Apoptosis by Constitutive Photomorphogenic 1 (COP1)
Joanne K. Tobacman, InSug O‐Sullivan, Sumit Bhattacharyya, et al.
Research Square (Research Square) (2025)
Open Access
Updates on the Biological Heterogeneity of Mantle Cell Lymphoma
Andrew Ip, Maciej Kabat, Lindsay Fogel, et al.
Cancers (2025) Vol. 17, Iss. 4, pp. 696-696
Open Access
A ROR1 targeted bispecific T cell engager shows high potency in the pre-clinical model of triple negative breast cancer
Fan Wang, Weina Li, Guohui Han, et al.
Breast Cancer Research (2025) Vol. 27, Iss. 1
Open Access
Novel macromolecule CPD4 suppresses cell proliferation and metastasis of triple-negative breast cancer by targeting ROR1 protein
Tram M. Ta, Victoria L. Reed, Shradheya R. R. Gupta, et al.
International Journal of Biological Macromolecules (2025) Vol. 310, pp. 143301-143301
Closed Access
Antibody-drug conjugates for lymphoma patients: preclinical and clinical evidences
Marilia Barreca, Noémie Lang, Chiara Tarantelli, et al.
Exploration of Targeted Anti-tumor Therapy (2022), pp. 763-794
Open Access | Times Cited: 18
Non-canonical WNT5A-ROR signaling: New perspectives on an ancient developmental pathway
Sara E. Konopelski, Srisathya Srinivasan, Courtney A. Dreyer, et al.
Current topics in developmental biology/Current Topics in Developmental Biology (2023), pp. 195-227
Closed Access | Times Cited: 9
Targeting the tumor microenvironment for treating double-refractory chronic lymphocytic leukemia
Richard Lewis, Alexander F. vom Stein, Michael Hallek
Blood (2024) Vol. 144, Iss. 6, pp. 601-614
Open Access | Times Cited: 3
A scalable, spin‐free approach to generate enhanced induced pluripotent stem cell–derived natural killer cells for cancer immunotherapy
Gustavo Rodrigues Rossi, Jane Sun, Cheng‐Yu Lin, et al.
Immunology and Cell Biology (2024)
Open Access | Times Cited: 3
Practical Management of Richter Transformation in 2023 and Beyond
Christine E. Ryan, Matthew S. Davids
American Society of Clinical Oncology Educational Book (2023), Iss. 43
Closed Access | Times Cited: 8
Page 1 - Next Page

Scroll to top